R. Agabio, J. M. Sinclair, G. Addolorato, H. Aubin, E. M. Beraha et al., Baclofen for the treatment of alcohol use disorder: the Cagliari Statement, Lancet Psychiatry, vol.5, issue.12, pp.30303-30304, 2018.

Y. Avraham, N. Grigoriadis, T. Poutahidis, L. Vorobiev, I. Magen et al., Cannabidiol improves brain and liver function in a fulminant hepatic failure-induced model of hepatic encephalopathy in mice, Br. J. Pharmacol, vol.162, issue.7, pp.1650-1658, 2011.

M. Bühler and K. Mann, Alcohol and the human brain: a systematic review of different neuroimaging methods, Alcohol Clin. Exp. Res, vol.35, issue.10, pp.1771-1793, 2011.

L. A. Batista and F. A. Moreira, Cannabinoid CB1 receptors mediate the anxiolytic effects induced by systemic alprazolam and intra-periaqueductal gray 5-HT1A receptor activation, Neurosci Lett, vol.703, pp.5-10, 2019.

M. M. Bergamaschi, R. H. Queiroz, M. H. Chagas, D. C. De-oliveira, B. S. De-martinis et al., Cannabidiol reduces the anxiety induced by simulated public speaking in treatment-naïve social phobia patients, Neuropsychopharmacology, vol.36, issue.6, pp.1219-1226, 2011.

T. Bisogno, L. De-petrocellis, D. Marzo, and V. , Fatty acid amide hydrolase, an enzyme with many bioactive substrates. Possible therapeutic implications, Curr Pharm. Des, vol.8, issue.7, pp.533-547, 2002.

G. W. Booz, Cannabidiol as an emergent therapeutic strategy for lessening the impact of inflammation on oxidative stress. Free Radic, Biol. Med, vol.51, issue.5, pp.1054-1061, 2011.

A. C. Campos and F. S. Guimarães, Evidence for a potential role for TRPV1 receptors in the dorsolateral periaqueductal gray in the attenuation of the anxiolytic effects of cannabinoids, Prog. Neuro-Psychopharmacology Biol. Psychiatry, vol.33, issue.8, pp.1517-1521, 2009.

A. C. Campos, Z. Ortega, J. Palazuelos, M. V. Fogaça, D. C. Aguiar et al., The anxiolytic effect of cannabidiol on chronically stressed mice depends on hippocampal neurogenesis: involvement of the endocannabinoid system, Int. J. Neuropsychopharmacol, vol.16, issue.6, pp.1407-1419, 2013.

A. C. Campos, M. V. Fogaça, A. B. Sonego, and F. S. Guimarães, , 2016.

, Cannabidiol, neuroprotection and neuropsychiatric disorders, Pharmacol Res, vol.112, pp.119-127

E. J. Carrier, J. A. Auchampach, and C. J. Hillard, Inhibition of an equilibrative nucleoside transporter by cannabidiol: a mechanism of cannabinoid immunosuppression, Proc. Natl. Acad. Sci. U S A, vol.103, issue.20, pp.7895-7900, 2006.

A. Castillo, M. R. Tolón, J. Fernández-ruiz, J. Romero, and J. Martinez-orgado, The neuroprotective effect of cannabidiol in an in vitro model of newborn hypoxic-ischemic brain damage in mice is mediated by CB2and adenosine receptors, Neurobiol. Dis, vol.37, issue.2, pp.434-440, 2010.

K. A. Chen, M. A. Farrar, M. Cardamone, and J. A. Lawson, Cannabis for paediatric epilepsy: challenges and conundrums, Med. J. Aust, vol.208, issue.3, pp.132-136, 2018.

D. Silva, V. K. De-freitas, B. S. Da-silva-dornelles, A. Nery, L. R. Falavigna et al., Cannabidiol normalizes caspase 3, synaptophysin, and mitochondrial fission protein DNM1L expression levels in rats with brain iron overload: implications for neuroprotection, Mol. Neurobiol, vol.49, issue.1, pp.222-233, 2014.

D. Liput, Transdermal delivery of cannabidiol attenuates binge alcohol-induced neurodenegeneration in a rodent model of an alcohol use disorder, Acc. Chem. Res, vol.45, issue.6, pp.788-802, 2008.

D. De-filippis, T. Iuvone, A. Esposito, G. Steardo, L. Herman et al., Effect of cannabidiol on sepsis-induced motility disturbances in mice: involvement of CB receptors and fatty acid amide hydrolase, Neurogastroenterol. Motil, vol.20, issue.8, pp.919-927, 2008.

L. De-petrocellis, A. Ligresti, A. S. Moriello, M. Allarà, T. Bisogno et al., Effects of cannabinoids and cannabinoid-enriched Cannabis extracts on TRP channels and endocannabinoid metabolic enzymes, Br. J. Pharmacol, vol.163, issue.7, pp.1479-1494, 2011.

D. G. Deutsch, A personal retrospective: elevating anandamide (AEA) by targeting fatty acid amide hydrolase (FAAH) and the fatty acid binding proteins (FABPs), Front. Pharmacol, vol.7, p.370, 2016.

O. Devinsky, M. R. Cilio, H. Cross, J. Fernandez-ruiz, J. French et al., Cannabidiol: pharmacology and potential therapeutic role in epilepsy and other neuropsychiatric disorders, Epilepsia, vol.55, issue.6, pp.791-802, 2014.

T. C. Durazzo, A. Mon, S. Gazdzinski, P. Yeh, and D. J. Meyerhoff, Serial longitudinal magnetic resonance imaging data indicate non-linear regional gray matter volume recovery in abstinent alcohol-dependent individuals, Addict. Biol, vol.20, issue.5, pp.956-967, 2015.

M. W. Elmes, M. Kaczocha, W. T. Berger, K. Leung, B. P. Ralph et al., Fatty acid-binding proteins (FABPs) are intracellular carriers for D9-tetrahydrocannabinol (THC) and cannabidiol (CBD), J. Biol. Chem, vol.290, issue.14, pp.8711-8721, 2015.

A. Lackner, C. Mathurin, P. Moreno, C. Spahr, L. Sterneck et al., EASL clinical practice guidelines: management of alcohol-related liver disease, J. Hepatol, vol.69, issue.1, pp.154-181, 2018.

J. Fernández-ruiz, O. Sagredo, M. R. Pazos, C. García, R. Pertwee et al., Cannabidiol for neurodegenerative disorders: important new clinical applications for this phytocannabinoid? Br, J. Clin. Pharmacol, vol.75, issue.2, pp.323-333, 2013.

R. Filev, D. S. Engelke, D. X. Da-silveira, L. E. Mello, S. et al., THC inhibits the expression of ethanol-induced locomotor sensitization in mice, Alcohol, vol.65, pp.31-35, 2017.

M. V. Fogaça, A. C. Campos, L. D. Coelho, R. S. Duman, and F. S. Guimarães, The anxiolytic effects of cannabidiol in chronically stressed mice are mediated by the endocannabinoid system: role of neurogenesis and dendritic remodeling, Neuropharmacology, vol.135, pp.22-33, 2018.

, Center for Drug Evaluation and Research, Food and Drugs Administration, 2018.

G. Gonzalez-cuevas, R. Martin-fardon, T. M. Kerr, D. G. Stouffer, L. H. Parsons et al., Unique treatment potential of cannabidiol for the prevention of relapse to drug use: preclinical proof of principle, Neuropsychopharmacology, vol.43, issue.10, pp.2036-2045, 2018.

G. Gruden, F. Barutta, G. Kunos, and P. Pacher, Role of the endocannabinoid system in diabetes and diabetic complications, Br. J. Pharmacol, vol.173, issue.7, pp.1116-1127, 2016.

F. S. Guimarhes, T. M. Chiaretti, F. G. Graeff, and A. W. Zuardi, Psychopharmacology antianxiety effect of cannabidiol in the elevated plusmaze, Psychopharmacology (Berl), vol.100, pp.558-559, 1990.

C. Hamelink, Comparison of cannabidiol, antioxidant, and diuretics in reversing binge ethanol-induced neurotoxicity, Acc. Chem. Res, vol.45, issue.6, pp.788-802, 2008.

A. C. Hansson, F. J. Bermúdez-silva, H. Malinen, P. Hyytiä, I. Sanchez-vera et al., Genetic impairment of frontocortical endocannabinoid degradation and high alcohol preference, Neuropsychopharmacology, vol.32, issue.1, pp.117-126, 2007.

T. A. Iseger and M. G. Bossong, A systematic review of the antipsychotic properties of cannabidiol in humans, Schizophr. Res, vol.162, issue.1-3, pp.153-161, 2015.

C. Ishikawa and T. Shiga, The postnatal 5-HT 1A receptor regulates adult anxiety and depression differently via multiple molecules, Prog. Neuro-Psychopharmacology Biol. Psychiatry, vol.78, pp.66-74, 2017.

T. Iuvone, G. Esposito, R. Esposito, R. Santamaria, M. Di-rosa et al., Neuroprotective effect of cannabidiol, a non-psychoactive component from Cannabis sativa, on ?-amyloid-induced toxicity in PC12 cells, J. Neurochem, vol.89, issue.1, pp.134-141, 2004.

J. Jamontt, A. Molleman, R. Pertwee, and M. Parsons, The effects of D 9 -tetrahydrocannabinol and cannabidiol alone and in combination on damage, inflammation and in vitro motility disturbances in rat colitis, Br. J. Pharmacol, vol.160, issue.3, pp.712-723, 2010.

J. Jeanblanc, P. Sauton, V. Jeanblanc, R. Legastelois, V. Echeverry-alzate et al., Face validity of a pre-clinical model of operant binge drinking: just a question of speed, Addict. Biol, 2018.

J. Jeanblanc, B. Rolland, F. Gierski, M. P. Martinetti, and M. Naassila, Animal models of binge drinking: behavior and clinical relevance. Neurosci. Alcohol 57-66, 2019.

B. A. Johnson, C. Seneviratne, X. Wang, N. Ait-daoud, and M. D. Li, Determination of genotype combinations that can predict the outcome of the treatment of alcohol dependence using the 5-HT 3 antagonist ondansetron, Am. J. Psychiatry, vol.170, issue.9, pp.1020-1031, 2013.

A. Juknat, M. Pietr, E. Kozela, N. Rimmerman, R. Levy et al., Differential transcriptional profiles mediated by exposure to the cannabinoids cannabidiol and D 9-tetrahydrocannabinol in BV-2 microglial cells, Br. J. Pharmacol, vol.165, issue.8, pp.2512-2528, 2012.

B. Julien, P. Grenard, F. Teixeira-clerc, J. T. Van-nhieu, L. Li et al., Antifibrogenic role of the cannabinoid receptor CB2 in the liver, Gastroenterology, vol.128, issue.3, pp.742-755, 2005.

T. Karl, B. Garner, and D. Cheng, The therapeutic potential of the phytocannabinoid cannabidiol for Alzheimer's disease, Behav. Pharmacol, vol.28, issue.2, pp.142-160, 2017.

G. M. Keating, Delta-9-tetrahydrocannabinol/cannabidiol oromucosal spray (Sativex ® ): a review in multiple sclerosis-related spasticity, Drugs, vol.77, issue.5, pp.563-574, 2017.

S. Khaksar and M. R. Bigdeli, Intra-cerebral cannabidiol infusion-induced neuroprotection is partly associated with the TNF-?/TNFR1/NF-?B pathway in transient focal cerebral ischaemia, Brain Inj, vol.31, pp.1932-1943, 2017.

E. Kozela, A. Juknat, and Z. Vogel, Modulation of astrocyte activity by cannabidiol, a nonpsychoactive cannabinoid, Int. J. Mol Sci, vol.18, issue.8, 2017.

R. B. Laprairie, A. M. Bagher, M. E. Kelly, and E. M. Denovan-wright, Cannabidiol is a negative allosteric modulator of the cannabinoid CB 1 receptor, Br. J. Pharmacol, vol.172, issue.20, pp.4790-805, 2015.

W. Lee and K. Erdelyi, Cannabidiol limits T cell-mediated chronic autoimmune myocarditis: implications to autoimmune disorders and organ transplantation, Mol. Med, vol.22, issue.1, p.1, 2016.

J. L. Lee, L. J. Bertoglio, F. S. Guimarães, and C. W. Stevenson, Cannabidiol regulation of emotion and emotional memory processing: relevance for treating anxiety-related and substance abuse disorders, Br. J. Pharmacol, vol.174, pp.3242-3256, 2017.

F. M. Leweke, D. Piomelli, F. Pahlisch, D. Muhl, C. W. Gerth et al., Cannabidiol enhances anandamide signaling and alleviates psychotic symptoms of schizophrenia, Transl. Psychiatry, vol.2, issue.3, p.94, 2012.

M. P. Lim, L. A. Devi, and R. Rozenfeld, Cannabidiol causes activated hepatic stellate cell death through a mechanism of endoplasmic reticulum stress-induced apoptosis, Cell Death Dis, vol.2, issue.6, pp.1-11, 2011.

I. Linares, A. W. Zuardi, L. C. Pereira, R. H. Queiroz, R. Mechoulam et al., Cannabidiol presents an inverted U-shaped dose-response curve in the simulated public speaking test, Braz. J. Psychiatry, vol.41, issue.1, pp.9-14, 2016.

S. Lotersztajn, F. Teixeira-clerc, B. Julien, V. Deveaux, Y. Ichigotani et al., CB2 receptors as new therapeutic targets for liver diseases, Br. J. Pharmacol, vol.153, issue.2, pp.286-289, 2008.

A. Louvet, F. Teixeira-clerc, M. Chobert, V. Deveaux, C. Pavoine et al., Cannabinoid CB2 receptors protect against alcoholic liver disease by regulating Kupffer cell polarization in mice, Hepatology, vol.54, issue.4, pp.1217-1226, 2011.

I. Magen, Y. Avraham, Z. Ackerman, L. Vorobiev, R. Mechoulam et al., Cannabidiol ameliorates cognitive and motor impairments in mice with bile duct ligation, J. Hepatol, vol.51, issue.3, pp.528-534, 2009.

P. Mandrekar, A. , and A. , Immunity and inflammatory signaling in alcoholic liver disease, Hepatol Int, vol.8, issue.S2, pp.439-446, 2014.

K. Mann, L. Torup, P. Sørensen, A. Gual, R. Swift et al., Nalmefene for the management of alcohol dependence: review on its pharmacology, mechanism of action and meta-analysis on its clinical efficacy, Eur. Neuropsychopharmacol, vol.26, issue.12, pp.1941-1949, 2016.

E. Martínez-pinilla, K. Varani, I. Reyes-resina, E. Angelats, F. Vincenzi et al., Binding and signaling studies disclose a potential allosteric site for cannabidiol in cannabinoid CB2 receptors, Front. Pharmacol, vol.8, p.744, 2017.

P. Massi, M. Valenti, A. Vaccani, V. Gasperi, G. Perletti et al., 5-Lipoxygenase and anandamide hydrolase (FAAH) mediate the antitumor activity of cannabidiol, a non-psychoactive cannabinoid, J. Neurochem, vol.104, issue.4, pp.1091-1100, 2008.

P. Massi, M. Solinas, V. Cinquina, and D. Parolaro, Cannabidiol as potential anticancer drug, Br. J. Clin. Pharmacol, vol.75, issue.2, pp.303-312, 2013.

P. Mcguire, P. Robson, W. J. Cubala, D. Vasile, P. D. Morrison et al., Cannabidiol (CBD) as an adjunctive therapy in schizophrenia: a multicenter randomized controlled trial, Am. J. Psychiatry, vol.175, issue.3, pp.225-231, 2018.

M. W. Meinhardt and W. H. Sommer, Postdependent state in rats as a model for medication development in alcoholism, Addict. Biol, vol.20, issue.1, pp.1-21, 2015.

C. F. Moore, M. D. Lycas, C. W. Bond, B. A. Johnson, and W. J. Lynch, Acute and chronic administration of a low-dose combination of topiramate and ondansetron reduces ethanol's reinforcing effects in male alcohol preferring (P) rats, Exp. Clin. Psychopharmacol, vol.22, issue.1, pp.35-42, 2014.

M. A. Mori, E. Meyer, L. M. Soares, H. Milani, F. S. Guimarães et al., Cannabidiol reduces neuroinflammation and promotes neuroplasticity and functional recovery after brain ischemia, 2017.

. Prog, Neuro-Psychopharmacology Biol. Psychiatry, vol.75, pp.94-105

A. Musella, D. Fresegna, F. R. Rizzo, A. Gentile, S. Bullitta et al., A novel crosstalk within the endocannabinoid system controls GABA transmission in the striatum, Sci. Rep, vol.7, issue.1, p.7363, 2017.

S. P. Neupane, Neuroimmune interface in the comorbidity between alcohol use disorder and major depression, Front. Immunol. Dec, vol.7, p.655, 2016.

R. S. O'shea, S. Dasarathy, and A. J. Mccullough, Practice Guideline Committee of the American Association for the Study of Liver Diseases, Practice Parameters Committee of the American College of Gastroenterology. Alcoholic liver disease, Hepatology, vol.51, issue.1, pp.307-328, 2010.

S. E. O'sullivan and D. A. Kendall, Cannabinoid activation of peroxisome proliferator-activated receptors: potential for modulation of inflammatory disease, Immunobiology, vol.215, issue.8, pp.611-616, 2010.

C. Palpacuer, R. Duprez, A. Huneau, C. Locher, R. Boussageon et al., Pharmacologically controlled drinking in the treatment of alcohol dependence or alcohol use disorders: a systematic review with direct and network meta-analyses on nalmefene, naltrexone, acamprosate, baclofen and topiramate, Addiction, vol.113, issue.2, pp.220-237, 2018.
URL : https://hal.archives-ouvertes.fr/hal-01696955

M. R. Pazos, N. Mohammed, H. Lafuente, M. Santos, E. Martínez-pinilla et al., Mechanisms of cannabidiol neuroprotection in hypoxic-ischemic newborn pigs: role of 5HT(1A) and CB2 receptors, Neuropharmacology, vol.71, pp.282-291, 2013.

R. G. Pertwee, The diverse CB 1 and CB 2 receptor pharmacology of three plant cannabinoids: D 9-tetrahydrocannabinol, cannabidiol and D 9-tetrahydrocannabivarin, Br. J. Pharmacol, vol.153, issue.2, pp.199-215, 2008.

M. Rajesh, P. Mukhopadhyay, S. Btkai, V. Patel, K. Saito et al., Cannabidiol attenuates cardiac dysfunction, oxidative stress, fibrosis, and inflammatory and cell death signaling pathways in diabetic cardiomyopathy, J. Am. Coll. Cardiol, vol.56, issue.25, pp.2115-2125, 2010.

J. Rehm, A. V. Samokhvalov, and K. D. Andshield, Global burden of alcoholic liver diseases, J. Hepatol, vol.59, issue.1, pp.160-168, 2013.

P. Rivera, E. Blanco, L. Bindila, F. Alen, A. Vargas et al., Pharmacological activation of CB2 receptors counteracts the deleterious effect of ethanol on cell proliferation in the main neurogenic zones of the adult rat brain, Front. Cell Neurosci, vol.9, p.379, 2015.

E. M. Rock, D. Bolognini, C. L. Limebeer, M. G. Cascio, S. Anavi-goffer et al., Cannabidiol, a non-psychotropic component of Cannabis, attenuates vomiting and nausea-like behaviour via indirect agonism of 5-HT(1A) somatodendritic autoreceptors in the dorsal raphe nucleus, Br. J. Pharmacol, vol.165, issue.8, pp.2620-2634, 2012.

B. Rolland, F. Paille, C. Gillet, A. Rigaud, R. Moirand et al., Pharmacotherapy for alcohol dependence: the 2015 Recommendations of the French Alcohol Society, Issued in Partnership with the European Federation of Addiction Societies, CNS Neurosci. Ther, vol.22, issue.1, pp.25-37, 2016.
URL : https://hal.archives-ouvertes.fr/hal-01276028

H. R. Ross, I. Napier, C. , and M. , Inhibition of recombinant human T-type calcium channels by delta9-tetrahydrocannabinol and cannabidiol, J. Biol. Chem, vol.283, issue.23, pp.16124-16134, 2008.

E. B. Russo, A. Burnett, B. Hall, and K. K. Parker, Agonistic properties of cannabidiol at 5-HT1a receptors, Neurochem. Res, vol.30, issue.8, pp.1037-1043, 2005.

D. Ryan, A. J. Drysdale, C. Lafourcade, R. G. Pertwee, and B. Platt, Cannabidiol targets mitochondria to regulate intracellular Ca2+ levels, J. Neurosci, vol.29, issue.7, pp.2053-2063, 2009.

E. Ryberg, N. Larsson, S. Sjögren, S. Hjorth, N. Hermansson et al., The orphan receptor GPR55 is a novel cannabinoid receptor, Br. J. Pharmacol, vol.152, issue.7, pp.1092-1101, 2009.

N. A. Santos, N. M. Martins, F. M. Sisti, L. S. Fernandes, R. S. Ferreira et al., The neuroprotection of cannabidiol against MPP+-induced toxicity in PC12 cells involves trkA receptors, upregulation of axonal and synaptic proteins, neuritogenesis, and might be relevant to Parkinson's disease, Toxicol. Vitr, vol.30, issue.1, pp.231-240, 2015.

M. A. Schuckit and V. Hesselbrock, Alcohol dependence and anxiety disorders: what is the relationship?, Am. J. Psychiatry, vol.151, issue.12, pp.1723-1734, 1994.

M. H. Schulte, J. Cousijn, T. E. Den-uyl, A. E. Goudriaan, W. Van-den-brink et al., Recovery of neurocognitive functions following sustained abstinence after substance dependence and implications for treatment, Clin. Psychol. Rev, vol.34, issue.7, pp.531-550, 2014.

C. Silvestri, D. Paris, A. Martella, D. Melck, I. Guadagnino et al., Two non-psychoactive cannabinoids reduce intracellular lipid levels and inhibit hepatosteatosis, J. Hepatol, vol.62, issue.6, pp.1382-1390, 2015.

M. Soyka and C. A. Müller, Pharmacotherapy of alcoholism-an update on approved and off-label medications, Expert Opin Pharmacother, vol.18, issue.12, pp.1187-1199, 2017.

C. P. Stanley, W. H. Hind, and S. E. Sullivan, Is the cardiovascular system a therapeutic target for cannabidiol? Br, J. Clin. Pharmacol, vol.75, issue.2, pp.313-322, 2013.

K. Stavro, J. Pelletier, and S. Potvin, Widespread and sustained cognitive deficits in alcoholism: a meta-analysis, Addict. Biol, vol.18, issue.2, pp.203-213, 2013.

C. A. Stern, T. R. Da-silva, A. M. Raymundi, C. P. De-souza, V. A. Hiroaki-sato et al., Cannabidiol disrupts the consolidation of specific and generalized fear memories via dorsal hippocampus CB 1 and CB 2 receptors, Neuropharmacology, vol.125, pp.220-230, 2017.

F. Teixeira-clerc, M. Belot, S. Manin, V. Deveaux, T. Cadoudal et al., Beneficial paracrine effects of cannabinoid receptor 2 on liver injury and regeneration, Hepatology, vol.52, issue.3, pp.1046-1059, 2010.
URL : https://hal.archives-ouvertes.fr/inserm-00519450

M. Tham, O. Yilmaz, M. Alaverdashvili, M. E. Kelly, E. M. Denovan-wright et al., Allosteric and orthosteric pharmacology of cannabidiol and cannabidiol-dimethylheptyl at the type 1 and type 2 cannabinoid receptors, Br. J. Pharmacol, vol.176, issue.10, pp.1455-1469, 2019.

M. D. Underwood, S. A. Kassir, M. J. Bakalian, H. Galfalvy, A. J. Dwork et al., Serotonin receptors and suicide, major depression, alcohol use disorder and reported early life adversity, Transl. Psychiatry, vol.8, issue.1, p.279, 2018.

A. Viudez-martínez, M. S. García-gutiérrez, C. M. Navarrón, M. I. Morales-calero, F. Navarrete et al., Cannabidiol reduces ethanol consumption, motivation and relapse in mice, Addict. Biol, vol.23, issue.1, pp.154-164, 2018.

A. Viudez-martínez, M. S. García-gutiérrez, A. I. Fraguas-sánchez, A. I. Torres-suárez, and J. Manzanares, Effects of cannabidiol plus naltrexone on motivation and ethanol consumption, Br. J. Pharmacol, vol.175, issue.16, pp.3369-3378, 2018.

Y. Wang, P. Mukhopadhyay, Z. Cao, H. Wang, D. Feng et al., Cannabidiol attenuates alcohol-induced liver steatosis, metabolic dysregulation, inflammation and neutrophil-mediated injury, Sci. Rep, vol.7, issue.1, pp.1-12, 2017.

Y. Wang, W. Lin, N. Wu, S. Wang, M. Chen et al., Structural insight into the serotonin (5-HT) receptor family by molecular docking, molecular dynamics simulation and systems pharmacology analysis, Acta Pharmacol. Sin, vol.0, pp.1-19, 2019.

K. Watanabe, H. Ogi, S. Nakamura, Y. Kayano, T. Matsunaga et al., Distribution and characterization of anandamide amidohydrolase in mouse brain and liver, Life Sci, vol.62, issue.14, pp.1223-1229, 1998.

K. Witkiewitz and K. E. Vowles, Alcohol and opioid use, co-use, and chronic pain in the context of the opioid epidemic: a critical review, Alcohol Clin. Exp. Res, vol.42, issue.3, pp.478-488, 2018.

, Global status report on alcohol and health, World Health Organization, 2018.

L. Yang, R. Rozenfeld, D. Wu, L. A. Devi, Z. Zhang et al., Cannabidiol protects liver from binge alcohol-induced steatosis by mechanisms including inhibition of oxidative stress and increase in autophagy. Free Radic, Biol. Med, vol.68, pp.260-267, 2014.

T. V. Zanelati, C. Biojone, F. A. Moreira, F. S. Guimarães, and S. R. Joca, Antidepressant-like effects of cannabidiol in mice: possible involvement of 5-HT 1A receptors, Br. J. Pharmacol, vol.159, issue.1, pp.122-128, 2010.

S. Zhornitsky and S. Potvin, Cannabidiol in humans-the quest for therapeutic targets, Pharmaceuticals (Basel), vol.5, issue.5, pp.529-552, 2012.

X. Zou, T. C. Durazzo, and D. J. Meyerhoff, Regional brain volume changes in alcohol-dependent individuals during short-term and long-term abstinence, Alcohol Clin. Exp. Res, vol.42, issue.6, pp.1062-1072, 2018.